Tyrosine kinase inhibitor use and risk of neurodegenerative disease: A Swedish population‐based cohort study

by Clinical Neuropsychologist Online | Sunday, October 11, 2026 | Dementia

Abstract INTRODUCTION Effective disease-modifying therapies remain unavailable for neurodegenerative diseases (NDDs). Tyrosine kinase inhibitors (TKIs) indicated for chronic myeloid leukemia (CML) have been hypothesized to modulate the pathological mechanisms...

Associations between plasma biomarker levels and quantitative postmortem neuropathologic measures in Alzheimer’s disease and related dementias

by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia

Abstract INTRODUCTION Validation of Alzheimer’s disease blood-based biomarkers (BBMs) has relied largely on amyloid beta (Aβ) and tau positron emission tomography (PET), with limited quantitative neuropathologic correlation studies. We examined associations...

MIND diet–related plasma proteins are associated with Alzheimer’s disease risk

by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia

Abstract INTRODUCTION Adherence to the Mediterranean–Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) diet is associated with reduced dementia risk, but underlying mechanisms remain unclear. METHODS Plasma proteomics (SomaScan...

Spatiotemporal heterogeneity and dynamic evolution of microglial glucose metabolic reprogramming in Alzheimer’s disease

by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia

Abstract Alzheimer’s disease (AD) is accompanied by persistent disturbances in brain energy metabolism, and microglial glucose metabolic reprogramming constitutes an important link among pathological protein deposition, neuroinflammation, and impaired clearance....

Longitudinal associations of rapid eye movement (REM) sleep and slow‐wave sleep with plasma Alzheimer’s disease biomarkers

by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia

Abstract INTRODUCTION Data on how sleep architecture relates to progression of plasma Alzheimer’s disease biomarkers remains limited. METHODS Sixty-four cognitively unimpaired older adults (ages 55–90) underwent plasma collection twice 2.6 years apart and...

Plasma eMTBR‐tau243 as a disease biomarker across Alzheimer’s disease clinical phenotypes

by Clinical Neuropsychologist Online | Friday, October 9, 2026 | Dementia

Abstract INTRODUCTION The concentration of endogenous tau microtubule-binding region containing residue-243 in plasma (eMTBR-tau243) has been proposed to be a sensitive biomarker of tangle pathology in Alzheimer’s disease (AD). We assessed eMTBR-tau243 and...